It has often been said that extreme exercise can have negative impact on heart. After reading a study presented at the European Society of Cardiology, congress worries for the same might get reduced.
The research led by Dr. Xavier Jouven from the European Georges Pompidou Hospital in Paris has found that French riders part of the Tour de France live on an average six years more than other people.
Moreover, they also die less from cardiovascular problems. One of the other revelations was that doping does not pose major health risk at least in the short term.
After knowing the result, study researchers were of the view that doctors should now be positive about rigorous exercises. In order to reach at the above given result, study resaerchers have assessed 786 French competitors, who had taken part in the bicycle race from 1947 to 2012.
Their data was compared with average French males. It was found that bicycle racers were at 41% reduced risk to die in comparison to French males.
The study should become a source of motivation for people that they should exert themselves in order to live healthy as well as to add more years to life.
In a recent announcement, Sega has revealed that its Steam catalog of classic Genesis and Mega Drive games is being updated with a new 3D interface --- the Sega Mega Drive Classics Hub.
Announcing the Classics Hub, Sega said that the new...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
Electric vehicle manufacturer Tesla has said in a recent announcement that it is now offering free trials of its autopilot software on Model S and Model X cars. The free trials give the owners of Model S and Model X cars a chance to test...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
Tech giant Google has revealed in a recent announcement that its latest Nik Collection of photo...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
On Wednesday, European competition authorities unveiled...
The button white mushroom edited using CRISPR has...
In a Tuesday announcement, Supergiant Games studio’s...
According to a CNN report, the Federal Investigation...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).